Skip to main content

Table 2 Treatment characteristics before 125I seed implantation (n = 10)

From: Permanent interstitial 125I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment

 

Previous treatment

 

No.

Gender

Age (years)

Stagea

Pathology

Position of implant seeds (recurrent position)

Surgery (times)

EBRT (courses)

Previous cumulative dose (Gy)

Chemotherapy (cycles)

Recurrent timeb (months)

1

F

16

T1aN0M0G1

Fibrosarcoma

Right axilla

1

1

60

0

12

Right upper arm

2

M

20

T1aN1M0G1

Fibrosarcoma

Left neck and left supraclavicular

2

1

60

0

24

Before the left clavicle

left carotid artery

3

F

19

T2bN0M1G2

Fibrosarcoma

Maxillofacial and right eye socket

1

0

0

0

17

4

M

4

T1bN0M0G2

Alveolar soft tissue sarcoma

Left tongue root

0

1

57.5

16

10

Left tongue root and palatopharyngeal arch

5

M

14

T1bN0M0G1

Fibrosarcoma

Right shoulder and neck

1

1

58

0

8

6

M

20

T1aN0M0G1

Fibrosarcoma

Right chest wall

4

0

0

0

72

7

M

9

T1bN0M1G3

Primitive neuroectodermal tumor

Left mandible

1

0

0

12

17

8

M

16

T2bN1M0G2

Epithelioid sarcoma

Right thigh

3

0

0

0

1

9

F

6

T2bN0M1G2

Rhabdomyosarcoma

Pelvic

1

1

36

12

1

10

M

11

T2bN1M0G2

Alveolar soft tissue sarcoma

Right face

0

1

33

12

4

  1. aTumor node metastasis (TNM) stage according to the American Joint Committee on Cancer Staging Manual (2010); bRecurrent time is the interval between seed implantation and the last treatment